ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2018 to Q4 2025

Type / Class
Equity / Common Stock, $0.01 par value per share
Symbol
RCKT on Nasdaq
Shares outstanding
107,228,372
Price per share
$3.51
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
96,588,463
Total reported value
$314,789,901
% of total 13F portfolios
0%
Share change
+1,637,373
Value change
+$10,419,402
Number of holders
171
Price from insider filings
$3.51
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MAVERICK CAPITAL LTD 7.8% +52% $26,429,649 +$8,900,576 8,363,813 +51% Maverick Capital, Ltd. 30 Jun 2025
WELLINGTON MANAGEMENT GROUP LLP 0.9% -83% $7,895,181 -$48,317,346 1,004,476 -86% Wellington Management Group LLP 30 May 2025

As of 30 Sep 2025, 171 institutional investors reported holding 96,588,463 shares of ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT). This represents 90% of the company’s total 107,228,372 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT) together control 76% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RTW INVESTMENTS, LP 16% 17,687,772 0% 0.71% $57,662,137
MAVERICK CAPITAL LTD 7.9% 8,468,344 +1.2% 0.37% $27,606,801
BlackRock, Inc. 6.6% 7,114,371 -4.2% 0% $23,192,850
VANGUARD GROUP INC 6.4% 6,892,204 +13% 0% $22,468,585
MPM BIOIMPACT LLC 3.6% 3,903,381 +0.01% 2.1% $12,725,022
SUVRETTA CAPITAL MANAGEMENT, LLC 3.6% 3,843,333 -7.2% 0.38% $12,529,266
MORGAN STANLEY 3.4% 3,647,039 +15% 0% $11,889,347
MILLENNIUM MANAGEMENT LLC 3.3% 3,570,391 +52% 0.01% $11,639,475
Monaco Asset Management SAM 2.7% 2,892,261 +539% 3.5% $9,428,771
Newtyn Management, LLC 2.3% 2,502,863 +25% 1% $8,159,333
D. E. Shaw & Co., Inc. 2% 2,189,750 +121% 0.01% $7,138,585
JPMORGAN CHASE & CO 2% 2,097,033 +74% 0% $6,836,329
GEODE CAPITAL MANAGEMENT, LLC 1.8% 1,914,554 -5.7% 0% $6,242,766
TWO SIGMA ADVISERS, LP 1.7% 1,795,751 +20% 0.01% $5,854,148
STATE STREET CORP 1.6% 1,745,310 -10% 0% $5,689,711
CITADEL ADVISORS LLC 1.6% 1,670,927 +971% 0% $5,447,222
TWO SIGMA INVESTMENTS, LP 1.5% 1,609,682 -6.7% 0.01% $5,247,563
Balyasny Asset Management L.P. 1.2% 1,313,737 +897% 0.01% $4,282,783
GOLDMAN SACHS GROUP INC 1.2% 1,271,093 -19% 0% $4,143,763
Prosight Management, LP 1.2% 1,267,965 -20% 0.99% $4,133,566
PRICE T ROWE ASSOCIATES INC /MD/ 0.99% 1,061,295 -3.5% 0% $3,461,000
Qube Research & Technologies Ltd 0.95% 1,014,358 -34% 0% $3,306,807
AQR CAPITAL MANAGEMENT LLC 0.81% 873,247 +12% 0% $2,846,787
TANG CAPITAL MANAGEMENT LLC 0.79% 850,000 0% 0.11% $2,771,000
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.69% 744,074 +21% 0% $2,425,681

Institutional Holders of ROCKET PHARMACEUTICALS, INC. - Common Stock, $0.01 par value per share (RCKT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 459,455 $1,613,479 -$62,724 $3.51 11
2025 Q3 96,588,463 $314,789,901 +$10,419,402 $3.26 171
2025 Q2 94,974,795 $232,855,173 -$147,581,517 $2.45 194
2025 Q1 107,749,040 $722,024,357 -$52,696,378 $6.67 233
2024 Q4 109,632,268 $1,377,359,505 +$161,902,372 $12.57 222
2024 Q3 92,703,462 $1,709,382,927 +$19,027,944 $18.47 189
2024 Q2 91,217,786 $1,963,307,213 -$33,485,873 $21.53 176
2024 Q1 92,048,164 $2,479,705,726 +$111,013,838 $26.94 183
2023 Q4 89,005,050 $2,667,733,521 -$7,076,901 $29.97 192
2023 Q3 89,401,055 $1,831,770,744 +$255,347,743 $20.49 174
2023 Q2 76,338,609 $1,516,884,469 -$31,879,301 $19.87 162
2023 Q1 78,264,099 $1,340,378,412 +$44,795,861 $17.13 161
2022 Q4 75,910,257 $1,486,203,005 +$147,925,718 $19.57 167
2022 Q3 69,117,168 $1,101,781,707 +$65,989,396 $15.96 159
2022 Q2 64,545,073 $887,423,123 +$4,039,525 $13.76 141
2022 Q1 64,321,676 $1,019,794,471 +$10,531,491 $15.86 142
2021 Q4 63,097,635 $1,377,944,582 +$9,053,118 $21.83 141
2021 Q3 61,977,765 $1,849,734,470 -$24,640,220 $29.89 142
2021 Q2 61,808,292 $2,736,555,111 -$11,025,172 $44.29 144
2021 Q1 62,013,212 $2,752,442,865 -$22,930,130 $44.37 169
2020 Q4 61,952,909 $3,397,683,589 +$431,615,785 $54.84 172
2020 Q3 55,227,508 $1,262,686,245 +$19,995,693 $22.86 124
2020 Q2 53,342,815 $1,116,479,207 +$14,452,216 $20.93 113
2020 Q1 53,304,185 $743,593,762 +$12,202,337 $13.95 102
2019 Q4 51,691,134 $1,176,484,498 +$87,809,919 $22.76 116
2019 Q3 47,699,668 $554,996,335 -$32,553,222 $11.65 91
2019 Q2 49,065,584 $735,942,854 +$92,556,483 $15.00 96
2019 Q1 42,874,596 $750,971,351 +$16,305,705 $17.54 80
2018 Q4 42,105,260 $622,102,055 +$68,806,707 $14.82 86
2018 Q3 36,793,895 $905,863,120 +$70,641,682 $24.62 82
2018 Q2 31,064,522 $605,382,076 +$63,867,898 $19.63 75
2018 Q1 27,976,061 $502,091,019 +$502,091,019 $18.75 55